Clinical Trial Detail

NCT ID NCT04158700
Title A Study of LY3200882 and Pembrolizumab in Participants With Advanced Cancer
Recruitment Withdrawn
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Eli Lilly and Company
Indications

transitional cell carcinoma

hepatocellular carcinoma

lung non-small cell carcinoma

Therapies

LY3200882 + Pembrolizumab

Age Groups: senior adult

No variant requirements are available.